Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guadecitabine in Higher Risk MDS
NCT02131597Phase 2Completed
- Sponsor
- University of Texas MD Anderson Cancer Center
- Start
- Nov 2014
- Primary completion
- Jul 2024
- Modality
- DNA Intercalators/Alkylators, Metabolically Activated Prodrugs
- Countries
- 1
01
Overview
A Phase 2 trial of guadecitabine in myelodysplastic syndrome (MDS), sponsored by University of Texas MD Anderson Cancer Center. Started Nov 2014; status: completed.
02
Drugs
guadecitabine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on NCT02131597.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02131597.